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Comparative Efficacy versus Effectiveness of Initial
Antiretroviral Therapy in Clinical Trials
versus Routine Care
Justin S. Routman,1,a James H. Willig,2,a Andrew O. Westfall,4 Sarah R. Abroms,2 Mohit Varshney,2 Sunil Adusumilli,2
Jeroan J. Allison,3 Karen G. Savage,2 Michael S. Saag,2 and Michael J. Mugavero2
1University of Alabama School of Medicine, Divisions of 2Infectious Diseases and 3Preventive Medicine, Department of Medicine, and 4School
of Public Health, Department of Biostatistics, University of Alabama at Birmingham, Birmingham
Background. The applicability of clinical trial findings (efficacy) to the routine care setting (effectiveness) may
be limited because of study eligibility criteria and volunteer bias. Although well-chronicled in many conditions,
the efficacy versus effectiveness of antiretroviral therapy (ART) remains understudied.
Methods. A retrospective study of the University of Alabama at Birmingham 1917 Clinic Cohort evaluated
ART-naive patients who started ART from 1 January 2000 through 31 December 2006. Patients received ART
through clinical trials or routine care. Multivariable logistic and linear regression models were fit to evaluate factors
associated with virological failure (virological failure was defined as a viral load 150 copies/mL) and change from
baseline CD4+ cell count 6 and 12 months after ART initiation. Sensitivity analyses evaluated the impact of missing
data on outcomes.
Results. Among 570 patients starting ART during the study period, 121 (21%) enrolled in clinical trials, and
449 (79%) received ART via routine care. ART receipt through routine care was not associated with viral failure
at either 6 months (odds ratio [OR], 1.00; 95% confidence interval [CI], 0.54–1.86) or 12 months (OR, 1.56; 95%
CI, 0.80–3.05) in primary analyses. No statistically significant differences in CD4+ cell count responses at 6 and
12 months were observed.
Conclusions. Although marked differences in efficacy versus effectiveness have been observed in the therapeutic
outcomes of other conditions, our analyses found no evidence of such divergence among our patients who initiated
antiretroviral therapy for human immunodeficiency virus infection.
Randomized clinical trials (RCTs) are the cornerstone
of level I evidence-based medicine treatment recom-
mendations and provide the highest level of evidence
[1]. However, some RCT-tested interventions have not
performed as well when implemented in routine care
settings [2–5]. Factors such as selection bias introduced
by trial eligibility criteria and volunteer bias among
participants choosing to participate in research studies
have been linked to this discrepancy [2, 4–10]. Selected
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patient samples may show improved treatment out-
comes in trials (efficacy) when compared with the more
heterogeneous population treated through routine care
(effectiveness), raising concerns about the applicability
of RCT findings to routine care settings.
Efforts to characterize differential efficacy versus ef-
fectiveness of treatments have been undertaken in many
medical conditions [2, 4–6, 9, 10], yet this relationship
regarding antiretroviral therapy (ART) for human im-
munodeficiency virus (HIV) infection and AIDS has
been notably understudied, particularly in the contem-
porary ART era [11]. Although numerous studies have
separately evaluated either the efficacy or the effective-
ness of initial ART regimens when used in RCTs and
routine care, respectively, relatively few have studied the
comparative effectiveness of treatment modality (RCT
vs routine care) on outcomes among patients starting
ART in the same clinical setting. Therefore, we con-
ducted a retrospective study to evaluate the impact of
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receiving initial ART through a clinical trial versus through
routine care on short-term viral load and CD4+ cell outcomes
among ART-naive individuals initiating therapy. Because treat-
ment-naive ART studies are commonly available, are ingrained
in the culture of HIV care at many treatment centers, and
provide a means to access medications and laboratories at little
to no cost to patients, we hypothesized that volunteer bias
would be less apparent in an HIV-infected cohort, relative to
cohorts of patients with other diseases. Accordingly, we posited
that the sociodemographic composition of those treated
through clinical trials would be reflective of the larger clinic
population and mirror the characteristics of those patients who
received ART through routine care. We further hypothesized
that similar virological and CD4+ cell outcomes would be ob-
served between patients treated in clinical trials and those
treated through routine care because of the similarities in the
patient populations.
METHODS
Sample and procedure. Since 1988, the University of Alabama
at Birmingham (UAB) 1917 HIV/AIDS Clinic (1917 Clinic) has
provided HIV care for 16000 HIV-infected individuals. The
UAB 1917 HIV/AIDS Clinic Cohort Database Project (UAB
1917 Clinic Cohort), which was recently recognized for excel-
lence in information integrity [12], is a 100% quality controlled,
institutional review board–approved prospective clinical cohort
study that includes detailed sociodemographic, psychosocial,
and clinical information from HIV-infected patients receiving
primary HIV and subspecialty care at the clinic [13]. The 1917
Clinic uses a locally programmed electronic medical record
(EMR) that imports laboratory values from the central UAB
laboratory, requires electronic prescriptions for all medications,
and contains detailed encounter notes. Both the UAB 1917
Clinic Cohort and local EMR have been described in detail
elsewhere [14–16].
A dedicated clinical trials program and staff have been part
of the 1917 Clinic since its inception. At our center, RCTs for
antiretroviral-naive patients are frequently available and open
for enrollment. Prior to study enrollment, providers ascertain
patients’ willingness to learn more about clinical trial partici-
pation and refer interested patients to clinical trial study nurses
who screen patients and begin the informed consent process.
Once enrolled in a research study, patients receive additional
follow-up from study personnel (nurses, mid-level health care
providers, and physicians) as determined by specific study pro-
tocols, in addition to regular outpatient care at the clinic. Pa-
tients who initiate ART through routine care meet with a clinic
pharmacist to discuss their regimen. Otherwise, no specific
treatment protocol is in place, and all clinic and laboratory
follow-up is at the discretion of the primary health care pro-
vider (a nurse practitioner or infectious diseases fellow) and
attending physician.
Here, we present a retrospective study of the UAB 1917 Clin-
ic Cohort that evaluates antiretroviral-naive patients who initi-
ated ART from 1 January 2000 through 31 December 2006. Pa-
tients were categorized into 2 groups: those who initiated
ART through a clinical trial, and those who started treatment
through routine care. A comparison of viral load and CD4+
cell outcomes between these groups, efficacy in RCTs versus
effectiveness in routine care, was the primary focus of this study.
Patients whose initial ART regimen lasted longer than 14 days
were included.
Independent variables previously reported [17, 18] to impact
virological outcomes were chosen a priori and included socio-
demographic characteristics (age, sex, race, HIV risk factor, and
health insurance status), psychosocial information (history of
affective mental disorder, defined as depression, anxiety, or bi-
polar disease; alcohol abuse; and substance abuse), and baseline
laboratory values (CD4+ cell count and plasma HIV load, with
viral load expressed in HIV RNA copies/mL). Outcome mea-
sures included plasma HIV virological failure (defined as a viral
load 150 copies/mL) and change from baseline CD4+ cell count
following ART initiation at 6-month and 12-month time points
(measure closest to time point in a90-day window was used).
Statistical analyses. Study variables were evaluated using
descriptive statistics to determine the distributions of variables
among patients who were treated through routine care versus
among those who received ART through a clinical trial. Bivar-
iate analyses were used to identify independent variables as-
sociated with clinical trial enrollment. Student’s t tests and x2
tests were applied for continuous and categorical variables, re-
spectively. Univariate and multivariable logistic regression mod-
els were fit to determine factors associated with virological fail-
ure at 6 and 12 months after ART initiation. Univariate and
multivariable linear regression models evaluated factors asso-
ciated with change from baseline CD4+ cell count value after
6 months and 12 months of therapy. Primary analyses included
only patients with available laboratory measures at the 6-month
and 12-month time points, and those with missing data were
excluded analytically (ie, missing equals missing).
To investigate the potential impact of missing data on study
outcomes, sensitivity analyses were conducted for viral load
and CD4+ cell count end points at both 6 and 12 months. For
those with missing viral load values, single imputation methods
were employed to assign outcomes [19]. Missing viral load
outcomes were based upon predicted probabilities of virological
failure derived from a multivariable model that included pa-
tients with available measures. A cut-point for assignment of
virological failure was selected erring on the side of misclas-
sification of patients with missing viral load data as having
experienced treatment failure (150 copies/mL). For missing
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Table 1. Treatment-Naive Trials and Number of Patients Enrolled at the University of Alabama at Birmingham 1917
HIV/AIDS Clinic from 1 January 2000 through 31 December 2006
Study name Study arm(s)
No. of
patients
ACTG 5202 1. ABC-3TC + EFV
2. ABC-3TC + ATV + RTV
3. FTC-TDF + EFV
4. FTC-TDF + ATV + RTV
54
ACTG 5142 1. LPVr + EFV
2. LPVr + 3TC + (ZDV or TDF or d4T XR)
3. EFV + 3TC + (ZDV or TDF or d4T XR)
20
ACTG 5095 1. ABC-3TC-ZDV + EFV
2. ABC-3TC-ZDV
3. 3TC-ZDV + EFV
11
Pfizer A4001026 “MERIT” 1. UK-427,857 (MVC) daily + ZDV-3TC
2. UK-427,857 (MVC) bid + ZDV-3TC
3. EFV + ZDV-3TC
11
AIEDRP AI-08–002 “ERADICATE” 1. d4T bid + 3TC bid + IDV q12h + NFV bid 8
Roche NR15720 1. 2 NRTIs per physician + SQV + RTV
2. 2 NRTIs per physician + EFV
6
Merck 021–00 “STARTMRK” 1. TDF-FTC + EFV
2. TDF-FTC + Mk-0518 (RAL)
4
BI-IATEC 2NN 1. 3TC + d4T + NVP (200 mg bid)
2. 3TC + d4T + NVP (400 mg daily)
3. 3TC + d4T + EFV (600 mg daily)
4. 3TC + d4T + NVP (400 mg daily) + EFV (800 daily)
2
ACTG 5146 1. All drugs at standard doses
2. PI dose adjusted per study + standard of care
1
AIEDRP AIN501 1. ABC-3TC-ZDV + LPVr
2. ABC-3TC-ZDV + LPVr + cyclosporine for the first 28 days of treatment
1
Glaxo-Welcome ESS40002 1. 3TC + d4T + NFV
2. 3TC + d4T + NFV + ZDV-3TC
3. 3TC + d4T + ABC + ZDV-3TC
1
Merck 094 “CRX463” 1. IDV bid + RTV bid + 3TC bid + d4T bid 1
Triangle FTC-301 1. FTC + (ddI or ddI-EC) + EFV
2. d4T + (ddI or ddI-EC) + EFV
1
NOTE. 2NN, 2 nonnucleoside reverse transcriptase inhibitors; 3TC, lamivudine; ABC, abacavir; ACTG, AIDS Clinical Trials Group; AIEDRP,
Acute Infection and Early Disease Research Program; ATV, atazanavir; BI, Boehringer Ingelheim; bid, twice daily; d4T, stavudine; d4T XR,
stavudine extended-release; ddI, didanosine; ddI-EC, time-release didanosine; EFV, efavirenz; FTC, emtricitabine; IATEC, International Antiviral
Therapy Evaluation Center; IDV, indinavir; LPV/r, ritonavir-boosted lopinavir; MVC, maraviroc; NFV, nelfinavir; NRTI, nucleoside reverse tran-
scriptase inhibitors; NVP, nevirapine; PI, protease inhibitor; q12h, every 12 h; RAL, raltegravir; RTV, ritonavir; SQV, saquinavir; TDF, tenofovir;
ZDV, zidovudine.
CD4+ cell count results, the last value recorded was carried
forward for sensitivity analyses. All statistical analyses were per-
formed using SAS, version 9.1.3 (SAS Institute), and statistical
significance was defined as .P ! .05
RESULTS
Among 570 ART-naive patients who initiated therapy from 1
January 2000 through 31 December 2006, 21% ( ) werenp 121
treated through a clinical trial, and 79% ( ) were treatednp 449
through routine care. Patients participated in 13 clinical trials
during the study period, including 4 Adult AIDS Clinical Trial
Group (ACTG) studies, which enrolled 86 (71%) of the 121
patients treated through RCTs (Table 1). Overall, most patients
were between the ages of 31 and 49 years (66% of patients),
male (77%), black (54%), had no health insurance (37%), and
were men who have sex with men (MSM; 51%). Baseline CD4+
cell count values were !200 cells/mm3 in 56% of patients,
whereas a baseline viral load !100,000 copies/mL was found
in 63% of individuals. Patient histories included diagnoses of
affective mental health disorders in 47%, substance abuse in
23%, alcohol abuse in 16%, and opportunistic infections in
31%. The most commonly used third drug was a nonnucleoside
reverse-transcriptase inhibitor (NNRTI; 66%) (Table 2).
In bivariate analysis, clinical trial enrollment was more com-
mon among patients with higher baseline CD4+ cell count val-
ues (61% of patients in clinical trials vs 40% of patients re-
ceiving routine care had CD4+ cell counts 1200 cells/mm3).
Black patients were significantly less likely than others to par-
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Table 2. Baseline Characteristics and Bivariate Analysis of Factors Associated with
Clinical Trial Participation among 570 Antiretroviral Therapy–Naive Patients Who Initiated
Therapy at the University of Alabama at Birmingham 1917 HIV/AIDS Clinic from 1 January
2000 through 31 December 2006
Characteristic
All patients
(n p 570)
Routine
care group
(n p 449)
Clinical
trial group
(n p 121) Pa
Age .21
30 Years 131 (23) 103 (23) 28 (23)
31–49 Years 376 (66) 291 (65) 85 (70)
50 Years 63 (11) 55 (12) 8 (7)
Sex .38
Male 440 (77) 343 (76) 97 (80)
Female 106 (23) 106 (24) 24 (20)
Race !.001
White 263 (46) 185 (41) 78 (64)
Black 307 (54) 264 (59) 43 (36)
HIV infection risk factor .04
Heterosexual sex 231 (41) 194 (44) 37 (31)
MSM 289 (51) 216 (49) 73 (61)
IDU 42 (8) 33 (7) 9 (8)
Baseline CD4+ cell count !.001
!50 cells/mm3 172 (31) 148 (34) 24 (20)
50–199 cells/mm3 141 (25) 117 (27) 24 (20)
200–350 cells/mm3 154 (27) 111 (25) 43 (35)
1350 cells/mm3 93 (17) 63 (14) 30 (25)
Baseline viral load .24
!100,000 plasma HIV RNA copies/mL 353 (63) 272 (62) 81 (68)
100,000 plasma HIV RNA copies/mL 203 (37) 165 (38) 38 (32)
Health insurance .11
Private 280 (49) 216 (48) 64 (53)
Public 81 (14) 71 (16) 10 (8)
Uninsured 209 (37) 162 (36) 47 (39)
Affective mental health disorder .08
No 304 (53) 248 (55) 56 (46)
Yes 266 (47) 201 (45) 65 (54)
Substance abuse .56
No 441 (77) 345 (77) 96 (79)
Yes 129 (23) 104 (23) 25 (21)
Alcohol abuse .38
No 480 (84) 375 (84) 105 (87)
Yes 90 (16) 74 (16) 16 (13)
Virological failureb
At 6 months 156 (33) 123 (34) 33 (29) .31
At 12 months 137 (32) 108 (33) 29 (27) .20
Change in CD4+ cell count, mean cells/mm3 (SD)
At 6 months 120  121 115  123 137  115 .39
At 12 months 175  153 171  158 187  139 .11
Opportunistic infection !.001
Yes 177 (31) 157 (35) 20 (17)
No 393 (69) 292 (65) 101 (83)
Third drug !.001
NRTI 50 (9) 50 (11) 0 (0)
PI 46 (8) 36 (8) 10 (8)
PIr 76 (13) 33 (7) 43 (36)
NNRTI 379 (66) 330 (74) 49 (41)
Unknown/other 19 (3) 0 (0) 19 (16)
NOTE. Data are no. (%) of patients, unless otherwise indicated. HIV, human immunodeficiency virus;
IDU, injection drug use; MSM, men who have sex with men; NNRTI, nonnucleoside reverse-transcriptase
inhibitor; NRTI, nucleoside reverse-transcriptase inhibitor; PI, protease inhibitor; PIr, ritonavir-boosted pro-
tease inhibitor; Unknown/other, currently blinded, raltegravir, or maraviroc.
a By x2 and Student’s t tests.
b Virological failure was defined as a viral load 150 plasma HIV RNA copies/mL.
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Table 3. Factors Associated with 6-Month and 12-Month Virological Failure following Antiretroviral Therapy (ART) Initiation among
ART-Naive Patients Who Initiated Therapy at the University of Alabama at Birmingham 1917 HIV/AIDS Clinic from 1 January 2000
through 31 December 2006 with an Available 6-Month Viral Load Measure
Variable
Virological failure at 6 months
(n p 479)
Virological failure at 12 months
(n p 431)
Crude OR (95% CI) Adjusted OR (95% CI) Crude OR (95% CI) Adjusted OR (95% CI)
Clinical trial
No vs Yes 1.27 (0.80–2.01) 1.00 (0.54–1.86) 1.37 (0.84–2.22) 1.56 (0.80–3.05)
Age group, years
30 vs 50 1.93 (0.96–3.87) 1.98 (0.91–4.32) 1.14 (0.57–2.31) 0.78 (0.35–1.73)
31–49 vs 50 0.92 (0.49–1.74) 0.92 (0.46–1.86) 0.74 (0.40–1.39) 0.61 (0.30–1.22)
Sex
Female vs Male 0.83 (0.52–1.34) 0.81 (0.41–1.60) 1.56 (0.98–2.50) 1.09 (0.54–2.18)
Race
Black vs white 1.58 (1.07–2.32) 1.73 (1.07–2.82) 1.86 (1.23–2.81) 2.11 (1.27–3.53)
HIV infection risk factor
Heterosexual sex vs IDU 0.53 (0.25–1.12) 0.29 (0.11–0.81) 0.97 (0.42–2.25) 0.91 (0.31–2.70)
MSM vs IDU 0.68 (0.33–1.39) 0.46 (0.17–1.21) 0.74 (0.33–1.69) 0.95 (0.33–2.74)
Baseline CD4+ cell count, cells/mm3
!50 vs 1350 1.80 (1.01–3.22) 1.53 (0.78–3.01) 0.99 (0.55–1.81) 0.73 (0.36–1.46)
50–199 vs 1350 1.42 (0.77–2.62) 1.42 (0.71–2.83) 0.98 (0.52–1.83) 0.85 (0.42–1.71)
200–350 vs 1350 0.75 (0.40–1.43) 0.88 (0.44–1.76) 0.56 (0.29–1.08) 0.61 (0.30–1.23)
Baseline viral load, plasma HIV copies/mL
100,000 vs !100,000 2.55 (1.71–3.79) 2.51 (1.58–4.01) 1.74 (1.15–2.64) 1.65 (1.01–2.71)
Third drug
NRTI vs NNRTI 1.21 (0.61–2.42) 2.14 (0.97–4.71) 0.84 (0.38–1.85) 0.91 (0.38–2.17)
PI vs NNRTI 2.01 (1.00–4.04) 1.97 (0.89–4.34) 4.39 (2.06–9.33) 5.24 (2.30–11.92)
PIr vs NNRTI 1.22 (0.71–2.10) 1.29 (0.65–2.54) 1.39 (0.77–2.50) 1.80 (0.87–3.72)
Unknown/other vs NNRTI 0.48 (0.14–1.71) 0.49 (0.11–2.13) 0.90 (0.31–2.57) 1.50 (0.43–5.22)
Health insurance:
Uninsured vs private 1.39 (0.91–2.13) 1.21 (0.75–1.94) 1.36 (0.87–2.13) 1.19 (0.72–1.95)
Public vs private 2.37 (1.36–4.13) 2.06 (1.07–3.95) 1.94 (1.07–3.52) 1.29 (0.66–2.55)
Affective mental health disorder
Yes vs no 1.02 (0.70–1.49) 1.13 (0.72–1.75) 1.11 (0.74–1.66) 1.09 (0.69–1.73)
Substance abuse
Yes vs no 1.07 (0.67–1.70) 0.82 (0.42–1.61) 1.26 (0.78–2.05) 1.56 (0.81–2.99)
Alcohol abuse
Yes vs no 0.63 (0.36–1.11) 0.58 (0.30–1.12) 0.55 (0.30–1.01) 0.62 (0.31–1.24)
NOTE. Virological failure was defined as a viral load 150 plasma HIV RNA copies/mL. Univariate and multivariable logistic regression was performed using
a “missing equals missing” approach. CI, confidence interval; HIV, human immunodeficiency virus; IDU, injection drug use; MSM, men who have sex with men;
NNRTI, nonnucleoside reverse-transcriptase inhibitor; NRTI, nucleoside reverse-transcriptase inhibitor; OR, odds ratio; PI, protease inhibitor; PIr, ritonavir-boosted
protease inhibitor; Unknown/other, currently blinded, raltegravir, or maraviroc.
ticipate in clinical trials ( ). HIV risk factor impactedP ! .001
study enrollment, as well; among clinical trial patients, 61%
were MSM and 31% were heterosexual, whereas among rou-
tine care patients, 49% were MSM and 44% were heterosexual
( ). However, patient age, sex, baseline viral load value,Pp .04
insurance status, presence of an affective mental health disorder,
substance abuse and alcohol abuse were not associated with
clinical trial enrollment (Table 2).
Among patients with available viral load measures at 6
months, 66% of those treated through routine care and 71%
of those treated through clinical trials achieved virological sup-
pression (viral load !50 copies/mL); at 12 months, 67% and
73% achieved virological suppression, respectively. In primary
multivariable analysis (missing equals missing; Table 3), a sta-
tistically significant association between method of ART receipt
(routine care vs clinical trial) and virological failure was not
observed at either time point (routine care vs clinical trial [ref-
erent] 6-month OR, 1.00 [95% CI, 0.54–1.86]; 12-month OR,
1.56 [95% CI, 0.80–3.05]). Six-month and 12-month virolog-
ical failure were associated with black race (6-month OR, 1.73
[95% CI, 1.07–2.82]; 12-month OR, 2.11 [95% CI, 1.27–3.53])
and baseline viral load 1100,000 copies/mL (6-month OR, 2.51
[95% CI, 1.58–4.01]; 12-month OR, 1.65 [95% CI, 1.01–2.71]).
Compared with patients who had private health insurance,
those who had public health insurance had higher odds of
virological failure at 6 months (OR, 2.06; 95% CI, 1.07–3.95),
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Table 4. Sensitivity Analysis of Factors Associated with 6-Month and 12-Month Vi-
rological Failure following Antiretroviral Therapy (ART) Initiation among ART-Naive
Patients Who Initiated Therapy at the University of Alabama at Birmingham 1917 HIV/
AIDS Clinic from 1 January 2000 through 31 December 2006 (Imputation Approach)
Variable
Adjusted OR (95% CI)
Virological failure
at 6 months
(n p 570)
Virological failure
at 12 months
(n p 570)
Clinical trial
No vs yes 1.22 (0.68–2.19) 1.77 (0.98–3.23)
Age, years
30 vs 50 2.00 (0.98–4.06) 0.87 (0.42–1.80)
31–49 vs 50 0.79 (0.42–1.48) 0.74 (0.39–1.41)
Sex
Female vs male 0.87 (0.48–1.56) 0.87 (0.49–1.53)
Race
Black vs white 2.23 (1.44–3.46) 4.94 (3.13–7.80)
HIV infection risk factor
Heterosexual sex vs IDU 0.29 (0.12–0.70) 0.86 (0.35–2.10)
MSM vs IDU 0.47 (0.20–1.09) 0.84 (0.35–2.03)
Baseline CD4+ cell count, cells/mm3:
!50 vs 1350 1.48 (0.79–2.77) 0.70 (0.38–1.31)
50–199 vs 1350 1.41 (0.75–2.66) 0.89 (0.48–1.67)
200–350 vs 1350 1.14 (0.62–2.12) 0.73 (0.40–1.34)
Baseline viral load, plasma HIV RNA copies/mL
100,000 vs !100,000 2.58 (1.68–3.97) 1.33 (0.86–2.06)
Third drug
NRTI vs NNRTI 1.76 (0.88–3.52) 0.57 (0.27–1.18)
PI vs NNRTI 1.65 (0.81–3.37) 7.66 (3.49–16.81)
PIr vs NNRTI 1.01 (0.53–1.92) 1.42 (0.74–2.70)
Unknown/other vs NNRTI 0.75 (0.21–2.62) 1.36 (0.39–4.73)
Health insurance
Uninsured vs private 1.19 (0.78–1.82) 1.11 (0.72–1.71)
Public vs private 1.89 (1.05–3.39) 1.59 (0.88–2.86)
Affective mental health disorder
Yes vs no 0.89 (0.59–1.33) 0.84 (0.56–1.26)
Substance abuse
Yes vs no 1.09 (0.62–1.90) 1.74 (0.99–3.06)
Alcohol abuse
Yes vs no 0.56 (0.31–1.00) 0.71 (0.40–1.26)
NOTE. Virological failure was defined as a viral load 150 plasma HIV RNA copies/mL. Univariate
and multivariable logistic regression was performed using imputation for missing outcomes. CI, con-
fidence interval; HIV, human immunodeficiency virus; IDU, injection drug use; MSM, men who have
sex with men; NNRTI, nonnucleoside reverse-transcriptase inhibitor; NRTI, nucleoside reverse-tran-
scriptase inhibitor; OR, odds ratio; PI, protease inhibitor; PIr, ritonavir-boosted protease inhibitor; Un-
known/other, currently blinded, raltegravir, or maraviroc.
but not at 12 months (OR, 1.29; 95% CI, 0.66–2.55). When
compared with NNRTIs, only unboosted protease inhibitors
were associated with higher odds of 12-month virological fail-
ure (OR, 5.24; 95% CI, 2.30–11.92). No other study variables
were significantly associated with 6-month or 12-month vi-
rological failure in primary analyses.
Sensitivity analyses that used imputation to assign virological
outcomes to patients with missing values were performed (Ta-
ble 4). In multivariable sensitivity analysis, method of ART
receipt (routine care vs clinical trial) was not associated with
virological failure at 6 months (OR, 1.22; 95% CI, 0.68–2.19).
Although the association was not statistically significant, pa-
tients who received ART through routine care had a trend
toward increased odds of virological failure at 12 months (OR,
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1.77; 95% CI, 0.98–3.23). Additional sensitivity analyses using
a missing equals failure approach yielded largely consistent
findings, although, relative to the primary sensitivity analyses,
slightly higher (and statistically significant) odds of virological
failure (OR, 2.10; 95% CI, 1.21–3.66) were observed in the
routine care group at 12 months, because that group included
a higher proportion of patients with missing values (data not
shown).
The increased odds of virological failure associated with black
race, as well as with the use of an unboosted protease inhibitor
(vs NNRTI ) as a third drug, and the lack of statistically significant
associations with age, sex, history of mental health disorder, sub-
stance abuse, or alcohol abuse observed in primary analyses were
consistent in sensitivity analyses (Table 4).
Finally, univariate and multivariable linear regression anal-
yses of factors associated with 6-month and 12-month change
from baseline CD4+ cell count value were modeled (missing
equals missing; Table 5). Baseline viral load 1100,000 copies/
mL was associated with a significantly greater increase in CD4+
cell count ( at 6 months; at 12 months). TwelveP ! .001 Pp .03
months after initiation of ART, no other factors were associated
with a difference in CD4+ cell count response. Notably, similar
CD4+ cell count responses were observed in patients treated
through a clinical trial and those treated through routine care.
Sensitivity analyses (with the last value carried forward; Table
6) of CD4+ cell count outcomes yielded findings similar to those
of the primary analyses.
DISCUSSION
Among HIV-infected patients who received care at an academic
HIV clinic in the Southeastern United States, our primary anal-
ysis revealed similar virological suppression (defined as a viral
load !50 copies/mL) and CD4+ cell count responses in ART-
naive patients who initiated treatment through a clinical trial
and those who initiated treatment through routine care.
Though the efficacy versus effectiveness relationship has been
examined thoroughly in cardiac care [2, 4, 5], substance abuse
programs [20], and psychotherapy [9, 10, 21], it has been no-
tably understudied in HIV/AIDS therapy [11]. A comparison
of viral load suppression, CD4+ cell responses, and mortality
among patients who received the same protease inhibitor reg-
imens through the Danish Protease Inhibitor Study clinical trial
and routine care showed that trial participants had better re-
sponses to ART than did patients who received routine care
[3]. In contrast, we found that 6-month and 12-month viro-
logical failure and CD4+ cell count response were not statisti-
cally significantly different between patients who received ART
through a clinical trial and those who received treatment
through routine care in our study (Tables 3 and 5).
This study also sought to characterize factors associated with
clinical trial enrollment in an HIV-infected cohort. Consistent
with prior findings in other specialties [7, 8, 22, 23] and with
earlier studies involving HIV infection [24], we found that black
individuals were less likely to participate in clinical trials than
were white individuals ( ; Table 2). Previously identifiedP ! .001
factors that may contribute to these findings include mistrust
of physicians and researchers [22, 24–29], patient fears (eg,
being treated as “guinea pigs,” being subjected to purposeful
infection, or historical precedents such as the Tuskegee syphilis
study) [24–26, 28–31], and inequality in requests for research
participation among racial/ethnic minorities [23, 26, 31–34].
In addition to underrepresentation in clinical trial participation,
racial disparities in viral load outcomes were also observed.
Black race was associated with increased odds of virological
failure in our population at both 6 and 12 months in primary
and sensitivity analyses (Tables 3 and 4). Bivariate comparisons
of sociodemographic and clinical characteristics among patients
with missing versus available viral load and CD4+ cell count
values in both the routine care and clinical trial groups showed
a statistically significant increase in the frequency of missing
data among black patients who received ART through routine
care at both 6 and 12 months (data not shown). It has been
proposed that limited access to health care and increased fre-
quency of missed clinic appointments may contribute to the
poor clinical outcomes observed among black patients with
HIV infection [11, 15, 35, 36]; these factors may also impact
the availability of laboratory measures.
We found that individuals with public health insurance were
more likely than those with private insurance to experience 6-
month virological failure. These findings identify another vul-
nerable and underserved group at risk for worse health out-
comes. Consistent receipt of and adherence to ART among this
group with lower socioeconomic status may be complicated by
gaps in coverage imposed by public insurance programs [37]
and the need to balance the costs of therapy for an initially
asymptomatic illness with other economic priorities and com-
peting needs. Health care system reforms that facilitate the
acquisition and consistent receipt of therapy in vulnerable pop-
ulations with limited access to health care are an important
prerogative.
Regimen and clinical characteristics associated with virolog-
ical failure were also identified. Patients with drug regimens
that included unboosted protease inhibitors had a higher rate
of virological failure, which result is not surprising given the
multitude of data that illustrate the poor outcomes associated
with use of unboosted protease inhibitors, compared with other
ART strategies (Tables 3 and 4) [38–40]. Elevated baseline viral
load has also been linked to increased risk of subsequent vi-
rological failure [11, 41, 42], which is a finding echoed by our
study. With regards to analyses concerning the change from
initial CD4+ cell count value, only baseline viral load 1100,000
copies/mL was associated with a statistically significant CD4+
cell count change at 12 months (Tables 5 and 6).
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Table 5. Factors Associated with 6-Month and 12-Month Change from Baseline CD4+ Cell Count following Antiretroviral Therapy
(ART) Initiation among ART-Naive Patients Who Initiated Therapy at the University of Alabama at Birmingham 1917 HIV/AIDS Clinic
from 1 January 2000 through 31 December 2006
Variable
6-Month
change in CD4+
cell count,
mean cells/mm3 (SD) Adjusted P a
12-Month
change in CD4+
cell count,
mean cells/mm3 (SD) Adjusted P a
Clinical trial .63 .85
No 114.6  122.8 171.0  158.2
Yes 136.5  114.6 187.3  139.0
Age, years .62 .98
30 115.9  108.2 175.8  164.0
31–49 119.5  129.3 177.3  151.5
50 131.1  94.1 161.9  144.7
Sex .57 .15
Female 114.0  122.1 207.6  183.6
Male 121.6  121.0 165.9  142.5
Race .02 .64
Black 100.8  108.5 171.6  158.3
White 139.3  130.1 178.8  148.8
HIV infection risk factor .09 .46
Heterosexual sex 111.7  119.3 191.1  160.1
IDU 104.8  103.3 164.4  155.1
MSM 127.4  123.6 165.6  148.4
Baseline CD4+ cell count, cells/mm3 .01 .69
!50 98.2  70.9 174.6  115.0
50–199 126.1  104.9 170.6  132.2
200–350 137.9  126.6 179.1  172.3
1350 122.4  184.2 177.5  208.6
Baseline viral load, plasma HIV RNA copies/mL !.001 .03
100,000 140.7  133.3 193.3  160.4
!100,000 107.7  112.4 164.7  149.6
Third drug .87 .10
NNRTI 119.0  112.1 166.9  144.7
NRTI 96.2  150.4 127.6  170.7
PI 125.9  141.2 225.1  204.0
PIr 128.1  130.1 208.1  146.6
Unknown/other 146.9  124.7 188.1  126.2
Health insurance .08 .16
Uninsured 110.2  120.1 170.4  146.2
Public 98.4  100.3 159.3  141.4
Private 132.6  126.0 182.6  161.3
Affective mental health disorder .29 .42
No 120.7  123.1 164.8  153.7
Yes 119.1  119.4 185.3  152.9
Substance abuse .02 .37
No 115.4  117.4 172.5  149.3
Yes 136.6  133.4 185.2  168.0
Alcohol abuse .69 .43
No 118.9  119.4 174.7  154.7
Yes 125.1  130.7 178.1  147.9
NOTE. HIV, human immunodeficiency virus; IDU, injection drug use; MSM, men who have sex with men; NNRTI, nonnucleoside reverse-transcriptase inhibitor;
NRTI, nucleoside reverse transcriptase inhibitor; PI, protease inhibitor; PIr, ritonavir-boosted protease inhibitor; SD, standard deviation; Unknown/other, currently
blinded, raltegravir, or maraviroc.
a Multivariable linear regression; for patients with missing data, a “missing equals missing” approach was used.
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Table 6. Sensitivity Analysis of Factors Associated with 6-Month and 12-Month Change from Baseline CD4+ Cell Count following
Antiretroviral Therapy (ART) Initiation among ART-Naive Patients Who Initiated Therapy at the University of Alabama at Birmingham
1917 HIV/AIDS Clinic from 1 January 2000 through 31 December 2006 (Last Value Carried Forward)
Characteristic
6-Month
change in CD4+
cell count,
mean cells/mm3 (SD) Adjusted P a
12-Month
change in CD4+
cell count,
mean cells/mm3 (SD) Adjusted P a
Clinical trial .24 .33
No 96.4  120.2 141.7  155.8
Yes 129.8  115.6 182.7  138.6
Age, years .78 .98
30 99.9  108.1 149.9  159.6
31–49 104.0  127.1 153.4  152.9
50 109.6  98.9 137.7  141.0
Sex .52 .09
Female 96.1  119.5 173.8  182.9
Male 105.9  120.1 144.0  142.5
Race .001 .12
Black 81.8  105.4 134.9  155.1
White 129.0  130.4 168.9  148.9
HIV infection risk factor .28 .50
Heterosexual sex 94.1  116.8 156.1  161.9
IDU 89.8  102.4 133.6  147.1
MSM 113.0  123.2 150.2  147.1
Baseline CD4+ cell count, cells/mm3 .06 .88
!50 87.1  73.7 150.0  119.9
50–199 106.3  106.7 148.1  152.4
200–350 114.4  126.4 148.1  167.2
1350 111.9  179.3 160.7  203.8
Baseline viral load, plasma HIV RNA copies/mL !.001 .01
100,000 124.5  133.2 175.4  159.5
!100,000 92.9  110.8 137.9  148.6
Third drug .87 .21
NNRTI 101.8  111.8 145.6  142.9
NRTI 80.5  141.9 95.4  166.8
PI 101.2  136.0 184.7  200.4
PIr 122.8  129.9 181.4  155.3
Unknown/other 131.5  126.3 188.1  126.2
Health insurance .07 .08
Uninsured 93.3  117.4 141.3  147.0
Public 83.3  98.9 130.7  136.5
Private 117.1  125.8 163.2  160.8
Affective mental health disorder .86 .06
No 98.1  120.6 133.2  151.1
Yes 109.9  119.0 171.0  153.0
Substance abuse .21 .44
No 101.7  116.4 149.6  149.9
Yes 110.4  131.5 154.9  164.1
Alcohol abuse .63 .49
No 102.8  118.2 150.2  154.2
Yes 108.2  128.9 153.9  147.4
NOTE. IDU, injection drug use; MSM, men who have sex with men; NNRTI, nonnucleoside reverse-transcriptase inhibitor; NRTI, nucleoside reverse-tran-
scriptase inhibitor; PI, protease inhibitor; PIr, ritonavir-boosted protease inhibitor; Unknown/other, currently blinded, raltegravir, or maraviroc.
a Multivariable linear regression; for patients with missing values, the last recorded value was carried forward.
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In sensitivity analyses of virological outcomes using impu-
tation methods, significant differences in 6-month virological
failure were not observed between patients who were treat-
ed in clinical trials and those who received routine care, in
accordance with primary analyses (Table 4). However, at 12
months, ART receipt through routine care was associated with
a trend toward increased odds of virological failure (OR, 1.77;
95% CI, 0.98–3.23). We suspect that this trend may reflect the
greater frequency of missing viral load values among the routine
care group (in the routine care group, 126 [28%] of patients
had missing values; in the clinical trial group, 13 [11%] of
patients had missing values), which may relate to several factors.
Volunteer and selection bias for clinical trial participation may
result in a sample of patients who are more likely to attend
clinic appointments and have laboratory measures obtained
than are patients in the routine care population. Study selection
criteria are known to contribute to differences in clinical trial
enrollment rates among different groups [2, 5, 6, 8, 9, 24] and
may have played a role in the current study. Participation in
a clinical trial also entails close follow-up with study personnel.
Such close monitoring and aggressive rescheduling after missed
study visits is beyond the capacity of our clinic for all patients
in routine clinical care. In summary, regarding efficacy versus
effectiveness in HIV therapy, 6-month virological outcomes
were consistent in primary and sensitivity analyses, although a
trend toward differences in viral load outcomes appeared at 12
months in sensitivity analyses. By using 2 strategies to evaluate
the impact of missing data on virological outcomes, a more
complete understanding of the efficacy-effectiveness gap is ob-
tained, which underscores the importance of a comprehensive
approach.
Our findings should be interpreted with respect to the lim-
itations of our study. As a retrospective study from a single
HIV cohort, our findings may not be generalizable to other
national or international settings, although our analysis may
provide insights applicable to such settings. As with all obser-
vational studies, we were able to identify associations but cannot
attribute causality. Although we controlled for measured con-
founders using multivariable models, there is the potential for
unmeasured confounding, which is inherent to observational
studies and which may impact outcomes interpretation. Other
studies have implicated patient education level in contributing
to clinical trial participation [7, 8, 22, 24–28, 30, 31], but we
were unable to systematically ascertain this variable in our sam-
ple. Because of our modest sample size, we were able to assess
treatment modality (clinical trial vs routine care) but had in-
sufficient numbers to assess efficacy versus effectiveness at the
regimen level. Such analyses are on-going through larger, multi-
site cohort collaborations.
A notable strength of this study is the use of multiple strat-
egies to analyze the impact of missing data on outcomes, which
enabled a more comprehensive understanding of the efficacy
versus effectiveness relationship within the constraints of the
measurements available. Many prior studies of HIV outcomes
have neither explicitly stated the handling of missing data nor
evaluated the impact of missing data on outcomes interpre-
tation.
In conclusion, clinical research studies have played a vital
role in the improvement of HIV treatment and outcomes. How-
ever, it is critical to evaluate both the efficacy and the effec-
tiveness of therapy to ensure that the results obtained from
clinical trials are generalizable to other populations treated
through routine care. In primary analyses evaluating patients
with available measures, we found similar 6-month and 12-
month virological failure and CD4+ cell count responses among
antiretroviral-naive patients treated through routine care, com-
pared with responses among those patients who participated
in clinical trials. These findings provide insight into the efficacy-
effectiveness relationship of ART for HIV infection and suggest
that, in the contemporary treatment era, similar first-year re-
sponses are observed in treatment-naive patients who start ART
in clinical trials and in those who start ART in routine care.
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